

## **Camel-IDS appoints Thomas Ramdahl as Independent Director**

- *The appointment follows the EUR 37m Series A round and supports the next growth stage*
- *The Board now consists of Christina Takke (Chair), Karl Nägler, Mårten Steen, Morten Graugaard Døssing, Ohad Hammer, Jean-Louis Baudhuin, Thomas Ramdahl and Ruth Devenyns (CEO)*

*Brussels (Belgium), 17 May 2019*

Camel-IDS, a biotech company developing novel radiopharmaceuticals, today announced the appointment of Thomas Ramdahl, former Chief Executive Officer of Algeta, as an independent, non-executive director.

Dr Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA (Algeta), a Norwegian biotech company that was successful in researching, developing and launching a radiopharmaceutical for prostate cancer. When Dr Ramdahl joined Algeta, he was one of six employees at the time, and he played an instrumental role in its success, serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014 for US\$2.9 Billion.

During his time at Algeta, the company successfully completed Phase 1 and 2 clinical trials, as well as a pivotal Phase 3 multi-centre, multi-country, double blinded clinical trial that led to FDA approval and marketing approval of Algeta's lead product, Xofigo. Dr Ramdahl led Algeta as CEO through an initial public offering (IPO) on the Oslo Stock Exchange in 2007. He remained in this role until 2009, at which stage he transitioned to Chief Technology Officer, and then to Chief Operating Officer in 2013. After the acquisition by Bayer in 2014, Dr Ramdahl resumed the position of Managing Director of Algeta, before quickly shifting to Managing Director of Bayer in Norway, remaining in this role until October 2018.

Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. He gained his PhD in Environmental Chemistry from the University of Oslo in 1984 and an MSc in Organic Chemistry from the Norwegian Institute of Technology in 1979. He has also been engaged in executive training at IMD in Lausanne, Switzerland.

Dr Ramdahl commented on his appointment to Camel-IDS' Board, *"I am honored to join Camel's Board during an exciting time in the Company's evolution and growth and look forward to leveraging my experience within the radiopharmaceutical field. I am very excited about the lead product and the product pipeline with potential to provide clinically meaningful therapeutic relief to many patients living with cancer."*

Camel-IDS' Chair Christina Takke commented, *"We are very excited to have someone of Dr Ramdahl's experience and capability joining our Board. We believe that Thomas' unique experience of managing and growing a radiopharmaceutical company from start-up through to marketing approval of its lead product and a successful exit will be invaluable to our future growth."*

### **About Camel-IDS**

Camel-IDS is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing novel radiopharmaceuticals, using camelid single domain antibody fragments (sdAb) labeled with radioisotopes. The Company is advancing its lead product CAM-H2 towards a phase Ib/II trial targeting HER2-positive brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline. Breast cancer patients with tumors that overexpress HER2, a growth-promoting protein, can benefit from effective targeted treatments today, yet have a poor prognosis when the cancer progresses towards the brain. Camel-IDS' lead program CAM-H2 aims to effectively irradiate brain lesions while sparing healthy tissue, based on its unique technology platform that leverages the favorable tissue distribution of camelid derived single domain antibodies linked to radionuclides. The company's technology platform also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a high therapeutic dose for treatment.

Camel-IDS, a VUB spin-off company incorporated in 2014, secured EUR 37m in a Series A investment round in November 2018, led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel), BioMedPartners (Switzerland) and existing investors. For more information, please visit [www.camel-ids.com](http://www.camel-ids.com).

---

### **For further information, please contact:**

Ruth Devenyns, CEO Camel-IDS  
+32 496 57 90 32  
[info@camel-ids.com](mailto:info@camel-ids.com)